Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1) antibodies, have become pivotal in treating advanced cancers. While effective, they are associated with immune-related adverse events (irAEs). Ocular irAEs, including uveitis, are uncommon, and Vogt-Koyanagi-Harada (VKH)-like panuveitis is a rare but vision-threatening complication....
✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
No actionable change for audiology practice; this report concerns an ophthalmologic immune-related adverse event in oncology with no audiology content.
✦ Why It Matters ✦
This case has no relevance to the audiology field.
✦ Key Points ✦
- 01Case report of a rare eye inflammation side effect caused by the cancer immunotherapy drug Sintilimab.
- 02The condition mimics Vogt-Koyanagi-Harada syndrome, which can involve hearing loss, but this case does not report auditory involvement.
- 03No audiology or hearing health data are presented.
- 04Clinical implications are limited to oncology and ophthalmology teams.
✦ Research metadata ✦
- PMID
- 42518340
- DOI
- 10.3389/fphar.2026.1857320.
- Journal
- Frontiers in Pharmacology
- Publication type
- case_report
- Evidence level
- 4
- Sample size
- 1
- Population
- Single gastric cancer patient receiving anti-PD-1 immunotherapy (Sintilimab)
- Intervention
- Anti-PD-1 therapy (Sintilimab)
Primary outcomes
Characterisation of Vogt-Koyanagi-Harada-like uveitis as an immune-related adverse event